Timber Pharma Breakthrough Therapy Designation for TMB-001 for Congenital Ichthyosis

 Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial -

Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TMB-001, a topical isotretinoin formulated using the Company’s patented IPEG™ delivery system, for the treatment of congenital ichthyosis (CI).

https://finance.yahoo.com/news/timber-pharmaceuticals-receives-fda-breakthrough-120000350.html